Stevanato Group

Valuation Analysis

About the Company

Stevanato Group en bref

Stevanato Group (STVN) is currently trading at 17,25 € with a market capitalization of 4,7 Md €. The trailing P/E ratio stands at 33.64x, with a forward P/E of 23.8x. The 52-week range spans from 11,20 € to 24,33 €; the current price is 29.1% below the yearly high. Year-over-year revenue growth stands at +6.6%. The net profit margin stands at 11.75%.

💰 Dividende

Stevanato Group pays an annual dividend of 0,05 € per share, representing a yield of 0.3%. The payout ratio stands at 10.59%.

📊 Avis des analystes

10 analystes évaluent Stevanato Group (STVN) au consensus : Acheter. L'objectif de cours moyen est de 21,25 €, soit un potentiel de +23.17% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 15,21 € à 27,81 €.

Stevanato Group : la thèse d'investissement en détail

Stevanato Group (STVN) operates in the Healthcare — specifically Medical Instruments & Supplies — and is headquartered in Italy. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Wall Street consensus sits at Buy with an average price target implying roughly 23.17% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valorisation en contexte

At a PEG of 3.57, investors are paying more than three times the growth rate for each unit of earnings — that pricing assumes growth not only continues but accelerates from here.

À surveiller

• The forward P/E of 23.8x is meaningfully below the trailing 33.64x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 23.17% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

The price is in a transition zone relative to the moving averages — no clear signal.

Profil de risque

The data points to relatively defensive market behavior.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Stevanato Group?

Compare top-rated brokers — low fees, trusted providers, fully regulated.